413 related articles for article (PubMed ID: 29905375)
1. SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma.
Hüser L; Sachindra S; Granados K; Federico A; Larribère L; Novak D; Umansky V; Altevogt P; Utikal J
Int J Cancer; 2018 Dec; 143(12):3131-3142. PubMed ID: 29905375
[TBL] [Abstract][Full Text] [Related]
2. p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells.
Pietrobono S; De Paolo R; Mangiameli D; Marranci A; Battisti I; Franchin C; Arrigoni G; Melisi D; Poliseno L; Stecca B
J Biol Chem; 2022 Sep; 298(9):102353. PubMed ID: 35944584
[TBL] [Abstract][Full Text] [Related]
3. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
4. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.
Cohen JV; Sullivan RJ
Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297
[TBL] [Abstract][Full Text] [Related]
5. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
Capovilla M
Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
[TBL] [Abstract][Full Text] [Related]
6. The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Ramsdale R; Jorissen RN; Li FZ; Al-Obaidi S; Ward T; Sheppard KE; Bukczynska PE; Young RJ; Boyle SE; Shackleton M; Bollag G; Long GV; Tulchinsky E; Rizos H; Pearson RB; McArthur GA; Dhillon AS; Ferrao PT
Sci Signal; 2015 Aug; 8(390):ra82. PubMed ID: 26286024
[TBL] [Abstract][Full Text] [Related]
7. Targeting BRAF in melanoma: biological and clinical challenges.
Mandalà M; Voit C
Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
[TBL] [Abstract][Full Text] [Related]
8. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
9. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.
Rossi A; Roberto M; Panebianco M; Botticelli A; Mazzuca F; Marchetti P
Eur J Pharmacol; 2019 Nov; 862():172621. PubMed ID: 31446019
[TBL] [Abstract][Full Text] [Related]
10. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
11. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma.
Patel A; Garcia LF; Mannella V; Gammon L; Borg TM; Maffucci T; Scatolini M; Chiorino G; Vergani E; Rodolfo M; Maurichi A; Posch C; Matin RN; Harwood CA; Bergamaschi D
Cancer Res; 2020 Jun; 80(12):2676-2688. PubMed ID: 32291316
[TBL] [Abstract][Full Text] [Related]
12. Morusin enhances the antitumor activity of MAPK pathway inhibitors in BRAF-mutant melanoma by inhibiting the feedback activation of STAT3.
Zhao K; Dai Q; Wu J; Wei Z; Duan Y; Chen B
Eur J Cancer; 2022 Apr; 165():58-70. PubMed ID: 35219024
[TBL] [Abstract][Full Text] [Related]
13. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced expression of the RNA-binding protein HuR attenuates the adaptive response to BRAF inhibition in melanoma.
Merat R; Bugi-Marteyn A; Wrobel LJ; Py C; Daali Y; Schwärzler C; Liaudet N
Biochem Biophys Res Commun; 2019 Sep; 517(2):181-187. PubMed ID: 31279529
[TBL] [Abstract][Full Text] [Related]
16. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.
Amaral T; Sinnberg T; Meier F; Krepler C; Levesque M; Niessner H; Garbe C
Eur J Cancer; 2017 Mar; 73():93-101. PubMed ID: 28162869
[TBL] [Abstract][Full Text] [Related]
17. MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
Rose AA; Annis MG; Frederick DT; Biondini M; Dong Z; Kwong L; Chin L; Keler T; Hawthorne T; Watson IR; Flaherty KT; Siegel PM
Clin Cancer Res; 2016 Dec; 22(24):6088-6098. PubMed ID: 27515299
[TBL] [Abstract][Full Text] [Related]
18. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
19. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
20.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
[Next] [New Search]
